Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-15 4:45 pm Purchase | 13G | SURROZEN INC SRZN | RA CAPITAL MANAGEMENT L.P. | 323,662 9.99% | 323,662 (New Position) | View |
| 2024-04-12 6:52 pm Purchase | 13D | ELIEM THERAPEUTICS INC ELYM | RA CAPITAL MANAGEMENT L.P. | 13,189,736 47.5% | 10,555 (+0.08%) | View |
| 2024-04-12 4:24 pm Purchase | 13G | AUDENTES THERAPEUTICS INC BOLD | RA CAPITAL MANAGEMENT L.P. | 2,180,631 9.8% | 2,180,631 (New Position) | View |
| 2024-04-11 7:55 pm Purchase | 13G | CERVOMED INC CRVO | RA CAPITAL MANAGEMENT L.P. | 825,373 9.99% | 825,373 (New Position) | View |
| 2024-04-11 4:16 pm Purchase | 13D | ACRIVON THERAPEUTICS INC ACRV | RA CAPITAL MANAGEMENT L.P. | 8,359,102 27.1% | 3,541,743 (+73.52%) | View |
| 2024-04-04 7:04 pm Purchase | 13G | DYNE THERAPEUTICS INC DYN | RA CAPITAL MANAGEMENT L.P. | 5,213,661 6.4% | 5,213,661 (New Position) | View |
| 2024-04-01 7:33 pm Purchase | 13G | SERA PROGNOSTICS INC SERA | RA CAPITAL MANAGEMENT L.P. | 2,047,221 6.5% | 2,047,221 (New Position) | View |
| 2024-03-29 5:41 pm Purchase | 13D | NKARTA INC NKTX | RA CAPITAL MANAGEMENT L.P. | 13,848,371 18.9% | 6,016,031 (+76.81%) | View |
| 2024-03-29 4:14 pm Purchase | 13D | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 10,860,977 11.3% | 1,401,299 (+14.81%) | View |
| 2024-03-29 12:54 pm Purchase | 13G | ALTO NEUROSCIENCE INC ANRO | RA CAPITAL MANAGEMENT L.P. | 1,385,491 5.2% | 1,385,491 (New Position) | View |
| 2024-03-28 4:16 pm Purchase | 13D | LENZ THERAPEUTICS INC LENZ | RA CAPITAL MANAGEMENT L.P. | 4,250,856 16.6% | 4,250,856 (New Position) | View |
| 2024-03-25 4:18 pm Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | RA CAPITAL MANAGEMENT L.P. | 6,250,000 9.5% | 6,250,000 (New Position) | View |
| 2024-03-25 4:17 pm Purchase | 13G | CYBIN INC CYBN | RA CAPITAL MANAGEMENT L.P. | 58,139,535 7.7% | 58,139,535 (New Position) | View |
| 2024-03-18 4:46 pm Purchase | 13D | ELIEM THERAPEUTICS INC ELYM | RA CAPITAL MANAGEMENT L.P. | 13,179,181 47.5% | 2,778 (+0.02%) | View |
| 2024-03-11 7:56 pm Unchanged | 13D | PEPGEN INC PEPG | RA CAPITAL MANAGEMENT L.P. | 10,695,135 33.1% | 0 (Unchanged) | View |
| 2024-03-06 6:54 pm Purchase | 13D | JANUX THERAPEUTICS INC JANX | RA CAPITAL MANAGEMENT L.P. | 10,593,395 19.99% | 1,922,751 (+22.18%) | View |
| 2024-03-06 6:50 pm Purchase | 13D | 89BIO INC ETNB | RA CAPITAL MANAGEMENT L.P. | 14,254,298 14.8% | 1,378,443 (+10.71%) | View |
| 2024-02-27 4:19 pm Sale | 13D | CONNECT BIOPHARMA HLDGS LTD CNTB | RA CAPITAL MANAGEMENT L.P. | 0 0% | -3,062,871 (Position Closed) | View |
| 2024-02-26 4:17 pm Purchase | 13G | LARIMAR THERAPEUTICS INC LRMR | RA CAPITAL MANAGEMENT L.P. | 6,045,351 9.5% | 6,045,351 (New Position) | View |
| 2024-02-22 7:07 pm Unchanged | 13G | CYTEK BIOSCIENCES INC CTKB | RA CAPITAL MANAGEMENT L.P. | 6,809,404 5.2% | 0 (Unchanged) | View |